Jeremy Szafron: Welcome back to Investors Scene. Very excited to get an update from Psyched Wellness. We have the CEO here with us.
Jeffery Stevens: Thanks for having me back. It’s always a pleasure to update your audience and then hopefully our shareholders.
Jeremy Szafron: Speaking of shareholders, we have been updating the story when we first spoke to you. After that, we spoke to someone on your board who is well known who sits on Compass Pass board of directors and that is David Nutt. Honestly Jeff, before talking to Daivd, I didn’t understand the opportunity here.
I really want to stress the fact that there is a huge differentiator with the Amanita muscaria mushroom and for those who didn’t view the interview, I encourage you to do so. The biggest takeaway from this is that you are not breaking legislation, you are working with a legal mushroom and those timelines are very very much different here.
Jeffery Stevens: Oh for sure. We learn as well and the great thing we have done in the last 2months is we have really added some industry experts onto our advisory board. Professor Nutt first joined us as an advisory and just in the last month, has taken on the full board position. He was getting to know us and vice versa and got some comfort with doing things properly: toxicology assessment and preclinical studies.
Psyched Wellness is the first modern company to study Amanita muscaria mushroom
Jeffery Stevens: Professor Nutt is sitting on the board of a 25 million dollar company and he is passionate, as you can tell by the interview you had with him. He is passionate about the Amanita muscaria mushroom and we are the first company in the modern-day to study this and move it forward.
He believes and we believe, that there are similar health and mental health benefits to the mushroom that you will see. We are very excited because it’s a legal compound and we don’t have to change laws, we can just move the market and it’s a quicker path.
Jeremy Szafron: There are studies taking place and he has tons of experience in the field. He has worked with the compound before but hasn’t analyzed it to the place that you have taken it, which is into people’s homes. This product might have the ability to help with mental and physical health. Also, it will encourage people to be more social and have a more minute effect depending on the dosage. What are the plans? You have been making many strides.
Jeffery Stevens: We learn every week with this and with more data that we are consuming. Professor Nutt has hired one of his students to write a data graph of all the scientific papers on the Amanita muscaria mushroom. We are compiling that and Kevin joined our advisory board. He has written a book on the Amanita muscaria mushroom and is focused on its historical use of it, as well as its modern-day use and applications.
With that group, we will do a survey where we will collect more data and then move towards doing scientific studies on how the Amanita muscaria mushroom can help people with mental health issues like anxiety and brain fog and moving away from addictions.
We are excited to continue with the tincture and move into the health and wellness space, but we will also focus on the larger scientific side where we are going after these major health issues with a natural health product. This will be a great solution and once again, it’s a legal mushroom.
Jeremy Szafron: I mean, you have added some successful and amazing board members as you mentioned. Doctor David Nutt is the best in this field so it will be interesting seeing 2021. It sounds like since the inception since we first spoke, you have not only built out the team but it looks like the plan is coming together.
Jeffery Stevens: We had the benefit of prior to becoming public, we could do everything quietly because we knew we were the only ones working with the mushroom Amanita muscaria, and had something special. We had a good year head start over anyone else. We have all of this information collected and as we move further into our preclinical studies, we really believe that it will be a strong foundation to build off of it.
We just announced today that we brought on a new member to our advisory board. Aaron is an asset for us, specifically with his contacts and experience. There is a history and historical use of compounds in specific regions so his contact base opens up another part of the world for us to explore as we build the company.
Jeremy Szafron: 2021… if you could look into that crystal ball, it’s exciting times.
Jeffery Stevens: We are closing the year out strong and have cleaned up a lot of the early selling pressure when we started trading and as we continue to educate the market on the potential and opportunity we have with Amanita muscaria, I believe that you will see that the company will reset and we will have great opportunities. Other companies go after serious health problems and we have the team and compound to do the same. We need to educate people that Amanita muscaria is as powerful as a mental health tool and can be studied further.
Jeremy Szafron: Especially during COVID, hopefully, that will take a turn. I appreciate your time.
Jeffery Stevens: It’s my pleasure, thank you.